- Home
- TNYA vs XGN Comparison
TNYA vs XGN Comparison
Compare TNYA & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- XGN
- Stock Information
- Founded
- TNYA 2016
- XGN 2002
- Country
- TNYA United States
- XGN United States
- Employees
- TNYA N/A
- XGN N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- XGN Medical Specialities
- Sector
- TNYA Health Care
- XGN Health Care
- Exchange
- TNYA Nasdaq
- XGN Nasdaq
- Market Cap
- TNYA 74.7M
- XGN 86.6M
- IPO Year
- TNYA 2021
- XGN 2019
- Fundamental
- Price
- TNYA $1.11
- XGN $3.58
- Analyst Decision
- TNYA Strong Buy
- XGN Strong Buy
- Analyst Count
- TNYA 5
- XGN 2
- Target Price
- TNYA $17.50
- XGN $7.50
- AVG Volume (30 Days)
- TNYA 1.9M
- XGN 153.9K
- Earning Date
- TNYA 03-17-2025
- XGN 03-17-2025
- Dividend Yield
- TNYA N/A
- XGN N/A
- EPS Growth
- TNYA N/A
- XGN N/A
- EPS
- TNYA N/A
- XGN N/A
- Revenue
- TNYA N/A
- XGN $55,751,000.00
- Revenue This Year
- TNYA N/A
- XGN $7.13
- Revenue Next Year
- TNYA N/A
- XGN $19.14
- P/E Ratio
- TNYA N/A
- XGN N/A
- Revenue Growth
- TNYA N/A
- XGN 8.00
- 52 Week Low
- TNYA $0.86
- XGN $1.30
- 52 Week High
- TNYA $7.01
- XGN $6.22
- Technical
- Relative Strength Index (RSI)
- TNYA 44.41
- XGN 38.58
- Support Level
- TNYA $1.43
- XGN $3.63
- Resistance Level
- TNYA $1.12
- XGN $4.55
- Average True Range (ATR)
- TNYA 0.10
- XGN 0.50
- MACD
- TNYA 0.05
- XGN -0.13
- Stochastic Oscillator
- TNYA 65.70
- XGN 2.75
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.